Tesamorelin: The Complete Guide

Overview

Tesamorelin is a synthetic analog of human growth hormone–releasing hormone (GHRH), the hypothalamic peptide that signals the anterior pituitary gland to produce and release growth hormone (GH). Developed by Theratechnologies Inc., tesamorelin consists of the full 44-amino-acid sequence of endogenous GHRH with a trans-3-hexenoic acid modification at the N-terminus. This modification increases stability and resistance to enzymatic degradation while preserving the physiological mechanism of action (Falutz et al., 2007).

Tesamorelin is FDA-approved — one of the few peptides in this class to achieve full regulatory approval. It was approved in 2010 under the brand name Egrifta (later reformulated as Egrifta SV) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, a condition characterized by abnormal fat accumulation in the trunk and visceral compartment. This approval was based on two pivotal Phase 3 randomized controlled trials published in peer-reviewed journals (Falutz et al., 2007; Falutz et al., 2010).

Unlike direct growth hormone administration, tesamorelin stimulates the body's own pulsatile GH secretion pattern through the GHRH receptor. This distinction is clinically significant: exogenous GH provides a continuous, non-physiological hormone level, while tesamorelin preserves the natural pulsatile rhythm — the episodic peaks and troughs that characterize normal GH physiology. This pulsatile pattern is associated with a more favorable metabolic profile and reduced risk of GH-related side effects compared to direct GH replacement (Stanley et al., 2014).

Beyond its approved indication, tesamorelin has generated research interest for its effects on liver fat (non-alcoholic fatty liver disease), cognitive function, and body composition in non-HIV populations. These uses remain investigational.

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

GHRH Receptor Activation

Tesamorelin acts as an agonist at the growth hormone–releasing hormone receptor (GHRH-R), a G-protein-coupled receptor expressed primarily on somatotroph cells in the anterior pituitary gland. When tesamorelin binds to this receptor, it triggers an intracellular signaling cascade involving cyclic AMP (cAMP) and protein kinase A (PKA), which stimulates the synthesis, storage, and secretion of growth hormone (Stanley et al., 2014).

The trans-3-hexenoic acid modification at the N-terminus of tesamorelin confers greater resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage — the primary enzymatic pathway that degrades native GHRH in circulation. Native GHRH has a plasma half-life of approximately 6–8 minutes; tesamorelin's structural modification extends its bioactivity, allowing once-daily dosing to produce clinically meaningful GH elevations (Falutz et al., 2007).

Pulsatile Growth Hormone Release

A critical distinction between tesamorelin and direct GH administration is the preservation of pulsatile secretion. In normal physiology, GH is released in discrete pulses — primarily during sleep and in response to exercise, fasting, and hypothalamic GHRH signaling. This pulsatile pattern is important because:

• Receptor sensitivity: GH receptors in target tissues (liver, adipose tissue, muscle) respond differently to pulsatile vs. continuous GH exposure. Pulsatile GH preferentially activates lipolytic (fat-burning) pathways.
• IGF-1 regulation: Pulsatile GH produces a more physiological IGF-1 response compared to the sustained IGF-1 elevation seen with continuous GH infusion.
• Feedback preservation: Tesamorelin works within the hypothalamic-pituitary axis, meaning somatostatin-mediated negative feedback remains intact. This provides a natural ceiling on GH release, reducing the risk of supraphysiological GH levels (Stanley et al., 2014).

Visceral Fat Reduction

The primary clinical effect of tesamorelin — reduction of visceral adipose tissue (VAT) — is mediated through GH's lipolytic actions. Growth hormone stimulates hormone-sensitive lipase in adipocytes, promoting the breakdown of stored triglycerides into free fatty acids and glycerol. Visceral adipose tissue is particularly responsive to GH-mediated lipolysis because it has a higher density of GH receptors and greater lipolytic sensitivity compared to subcutaneous fat (Falutz et al., 2010).

This preferential effect on visceral fat is clinically relevant because visceral adiposity is more strongly associated with metabolic complications — insulin resistance, dyslipidemia, cardiovascular risk, and systemic inflammation — than subcutaneous fat.

IGF-1 and Downstream Effects

Tesamorelin-stimulated GH release leads to hepatic production of insulin-like growth factor 1 (IGF-1), which mediates many of GH's downstream effects:

• Hepatic fat metabolism: GH and IGF-1 signaling reduces hepatic de novo lipogenesis (new fat production in the liver) and promotes fatty acid oxidation, contributing to reduced liver fat content (Stanley et al., 2019).
• Body composition: IGF-1 promotes lean mass preservation and protein synthesis while GH drives lipolysis — the combined effect favors improved body composition (reduced fat, maintained or increased lean mass).
• Cognitive effects: IGF-1 receptors are widely expressed in the brain, particularly in the hippocampus. GH/IGF-1 signaling supports neurogenesis, synaptic plasticity, and neuronal survival — providing a mechanistic basis for the cognitive effects observed in clinical studies (Baker et al., 2012).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Phase 3 Trials: HIV-Associated Lipodystrophy

The FDA approval of tesamorelin was based on two pivotal multicenter, randomized, double-blind, placebo-controlled Phase 3 trials involving over 800 HIV-infected patients with excess abdominal fat accumulation.

• Trial 1 (Falutz et al., 2007): 412 HIV-infected patients with lipodystrophy were randomized to tesamorelin 2 mg or placebo daily for 26 weeks. The tesamorelin group demonstrated a statistically significant reduction in trunk fat (−15.2% vs. −0.6% for placebo, p < 0.001) as measured by CT scan. Visceral adipose tissue decreased significantly. IGF-1 levels increased, and the treatment was generally well tolerated (Falutz et al., 2007).
• Trial 2 (Falutz et al., 2010): 404 HIV-infected patients received tesamorelin 2 mg or placebo for 26 weeks, followed by a 26-week extension. Tesamorelin produced a −11% reduction in VAT compared to +3.9% for placebo (p < 0.001). Triglyceride levels improved. Trunk fat regained upon discontinuation, indicating that continued use is required to maintain benefits (Falutz et al., 2010).

Both trials demonstrated consistent, reproducible visceral fat reduction with a manageable side effect profile. The reversal of effect upon discontinuation is an important clinical consideration — tesamorelin manages but does not cure lipodystrophy-associated visceral adiposity.

Liver Fat and NAFLD/NASH

Tesamorelin has been studied for its effects on hepatic steatosis (fatty liver), a common comorbidity in both HIV-positive and general populations.

• Stanley et al. (2014): A randomized, double-blind, placebo-controlled trial in 61 HIV-infected patients with fatty liver showed tesamorelin reduced hepatic fat fraction by 37% (measured by proton magnetic resonance spectroscopy) compared to no significant change with placebo. The proportion of patients meeting criteria for hepatic steatosis resolution was significantly higher in the tesamorelin group (Stanley et al., 2014).
• Stanley et al. (2019): A 12-month randomized controlled trial (ACTG A5271) in HIV-infected patients with NAFLD demonstrated that tesamorelin prevented progression of hepatic fibrosis compared to placebo. The tesamorelin group showed stabilization of fibrosis scores while the placebo group showed worsening. Liver fat content decreased significantly with tesamorelin (Stanley et al., 2019).

These findings are notable because NAFLD is a major public health concern beyond the HIV population, and effective pharmacological treatments remain limited.

Cognitive Function

Growth hormone and IGF-1 signaling play established roles in brain health, and tesamorelin has been evaluated for cognitive effects:

• Baker et al. (2012): A randomized, double-blind, placebo-controlled trial in 152 older adults (both healthy and with mild cognitive impairment) evaluated the effects of a GHRH analog on cognition over 20 weeks. Treatment improved executive function, verbal memory, and cognitive processing speed compared to placebo. Effects were observed in both cognitively normal elderly adults and those with mild cognitive impairment (Baker et al., 2012).
• Cognition in HIV: Given that HIV-associated neurocognitive disorder (HAND) affects a significant proportion of people living with HIV, there is ongoing interest in whether tesamorelin's GH/IGF-1 effects could provide cognitive benefit in this population. Preliminary data suggest potential benefit, though larger dedicated trials are needed (Stanley et al., 2014).

Cardiovascular Biomarkers

• Triglycerides: Phase 3 trials demonstrated modest but statistically significant reductions in triglyceride levels with tesamorelin treatment, relevant given the elevated cardiovascular risk in HIV-associated lipodystrophy (Falutz et al., 2010).
• Inflammatory markers: Some studies have observed reductions in C-reactive protein (CRP) and other inflammatory biomarkers with tesamorelin, consistent with reduction in metabolically active visceral fat (Stanley et al., 2014).
• Carotid intima-media thickness (cIMT): Exploratory analyses have evaluated tesamorelin's effects on subclinical atherosclerosis markers, though definitive cardiovascular outcome data are not available.

Body Composition in Non-HIV Populations

While FDA approval is specific to HIV-associated lipodystrophy, tesamorelin's mechanism of action — stimulating endogenous GH release to reduce visceral fat — is not HIV-specific. Off-label interest has focused on:

• Age-related visceral fat accumulation and GH decline
• Metabolic syndrome with central adiposity
• Body composition optimization in the context of anti-aging medicine

Controlled clinical trial data supporting tesamorelin use in non-HIV populations for body composition endpoints remain limited.

Strengths of the Evidence Base

• Gold-standard trial design: Two Phase 3 randomized, double-blind, placebo-controlled trials with large sample sizes.
• Objective outcome measures: CT-scan-measured visceral fat, MRS-measured liver fat, validated cognitive testing — not subjective self-report.
• Peer-reviewed publication: Key trials published in high-impact journals (NEJM, JAMA, Archives of Neurology).
• Multi-center design: Results replicated across multiple clinical sites.
• Independent research groups: Studies conducted by multiple independent groups at major academic institutions.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indication

Egrifta SV (tesamorelin) is FDA-approved for the reduction of excess abdominal fat in adult HIV-infected patients with lipodystrophy. HIV-associated lipodystrophy is a well-characterized syndrome involving abnormal fat redistribution — with accumulation of visceral fat in the trunk (dorsocervical fat pad, abdominal compartment) and loss of subcutaneous fat in the face and extremities. This condition is associated with antiretroviral therapy, particularly older protease inhibitors and nucleoside reverse transcriptase inhibitors (Egrifta SV FDA Label).

The FDA label specifies that tesamorelin's limitations of use include: it is not indicated for weight loss management; effects on cardiovascular risk have not been established; and fat accumulation may recur upon discontinuation.

Off-Label and Investigational Uses

The following uses are reported in clinical practice but are not FDA-approved indications. They are based on published clinical research and provider experience.

How Tesamorelin Is Accessed

• Brand prescription (Egrifta SV): Available by prescription for the FDA-approved indication. Distributed through specialty pharmacies. Requires prior authorization from insurance for HIV-associated lipodystrophy.
• Compounding pharmacies: Tesamorelin is available through 503A and 503B compounding pharmacies for off-label use when prescribed by a licensed provider. Compounding pharmacy products are generally less expensive than branded Egrifta SV.
• Anti-aging / regenerative medicine clinics: Many clinics specializing in hormone optimization and anti-aging medicine prescribe compounded tesamorelin as part of GH-optimization protocols.

What Tesamorelin Is NOT Used For

• Weight loss: The FDA label explicitly states tesamorelin is not indicated for weight loss management. While it reduces visceral fat, it does not produce significant total body weight reduction.
• Growth hormone deficiency replacement: Tesamorelin stimulates endogenous GH release and requires a functioning pituitary. It is not a substitute for GH replacement in patients with confirmed pituitary insufficiency.
• Bodybuilding / performance enhancement: While tesamorelin increases GH and IGF-1 levels, it is not an anabolic agent in the bodybuilding sense. Its primary measurable effect is visceral fat reduction.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

FDA-Approved Dosing

Source: Egrifta SV Full Prescribing Information (FDA Label) · Phase 3 trial protocols: Falutz et al., 2007 · Falutz et al., 2010

Off-Label / Compounding Pharmacy Protocols

When prescribed off-label through compounding pharmacies, dosing protocols may vary based on provider preference and clinical goals:

Off-label protocols are based on clinical experience — not published controlled trials at these specific regimens.

Monitoring Requirements

The FDA label recommends the following monitoring during tesamorelin treatment:

• IGF-1 levels: Monitor at baseline and periodically during treatment. Discontinue if IGF-1 levels exceed the upper limit of the age-adjusted normal range and do not normalize with continued treatment. Sustained IGF-1 elevation may increase the risk of adverse effects.
• Glucose and HbA1c: GH can increase insulin resistance. Monitor blood glucose and HbA1c, particularly in patients with diabetes or pre-diabetes.
• Lipid panel: Assess triglycerides and other lipid markers at baseline and during treatment.
• Body composition: CT scan or DEXA to assess visceral fat changes (typically at baseline and after 3–6 months of treatment).

Administration

Egrifta SV is supplied as a lyophilized powder that requires reconstitution before injection. Preparation and injection technique should be demonstrated by your prescribing healthcare provider or pharmacist. The FDA-approved product includes detailed patient instructions for use.

Compounding pharmacy preparations may differ in formulation, concentration, and reconstitution requirements. Follow the specific instructions provided by your compounding pharmacy and prescriber.

Discontinuation

Clinical trials have demonstrated that visceral fat reduction reverses upon discontinuation of tesamorelin. In the Phase 3 extension study, patients rerandomized to placebo after 26 weeks of treatment experienced return of visceral fat to near-baseline levels (Falutz et al., 2010). This indicates that tesamorelin manages — but does not permanently resolve — excess visceral adiposity.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Results: What Clinical Trials Show

Clinical Trial Results

Visceral Fat Outcomes

The primary endpoint across Phase 3 trials was change in visceral adipose tissue measured by CT scan at the L4–L5 vertebral level — an objective, reproducible imaging measure. Key findings:

• Mean VAT reduction of approximately 15–18% compared to baseline
• Placebo-subtracted difference was statistically significant (p < 0.001)
• Effects were consistent across subgroups (sex, race, baseline VAT level, antiretroviral regimen)
• Subcutaneous fat was not significantly affected — the effect is preferential for visceral fat
• Total body weight did not change significantly, consistent with fat redistribution rather than weight loss

Liver Fat Outcomes

In the NAFLD study by Stanley et al. (2019):

• Hepatic fat fraction decreased by 37% from baseline with tesamorelin
• 32% of tesamorelin patients achieved resolution of hepatic steatosis vs. 6% with placebo
• Fibrosis did not progress in the tesamorelin group; 38% of placebo patients showed fibrosis progression
• NASH histological scores improved with tesamorelin (Stanley et al., 2019)

Cognitive Outcomes

In the Baker et al. (2012) cognitive trial:

• GHRH analog treatment improved executive function (Trail Making Test B: p = 0.005)
• Verbal memory improved (RAVLT total recall: p = 0.03)
• Effects observed in both cognitively normal elderly and those with mild cognitive impairment
• Cognitive benefit correlated with increases in IGF-1 levels (Baker et al., 2012)

User-Reported Experiences (Off-Label Use)

Individuals using tesamorelin off-label through compounding pharmacies commonly report:

• Reduced abdominal circumference within 4–8 weeks
• Improved sleep quality (possibly related to GH-mediated sleep architecture effects)
• Improved skin quality and elasticity
• Enhanced recovery from exercise
• Improved energy and sense of well-being

These reports are anecdotal and subject to the same limitations as any uncontrolled observations — placebo effect, selection bias, and confounding variables cannot be excluded.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Common Side Effects (From Phase 3 Trials)

Incidence data from the Egrifta SV prescribing information and pooled Phase 3 trial analysis (FDA Label).

IGF-1 Elevation

Tesamorelin increases IGF-1 levels as a direct consequence of its mechanism of action. This is an expected pharmacological effect, not an adverse event per se — but sustained elevation of IGF-1 above the age-adjusted normal range raises clinical concerns:

• Epidemiological association: Persistently elevated IGF-1 levels have been associated in epidemiological studies with increased risk of certain malignancies (prostate, breast, colorectal), though a causal relationship has not been established (Stanley et al., 2014).
• Monitoring requirement: The FDA label recommends monitoring IGF-1 at baseline and periodically during treatment. If IGF-1 exceeds the upper limit of the age-adjusted normal range and does not normalize, discontinuation should be considered.
• Acromegaly-like effects: Theoretically, sustained supraphysiological GH/IGF-1 could produce acromegaly-like effects (soft tissue swelling, carpal tunnel syndrome, joint pain) — though this has not been reported at the approved 2 mg dose in clinical trials.

Glucose Metabolism

Growth hormone is a counter-regulatory hormone that can impair insulin sensitivity. In Phase 3 trials:

• Fasting glucose and HbA1c showed small, generally non-significant increases in the tesamorelin group
• New-onset diabetes was not significantly more common with tesamorelin vs. placebo
• Patients with pre-existing diabetes should be monitored more closely, as GH effects may worsen glycemic control
• The FDA label includes glucose monitoring in its recommended assessments (FDA Label)

Hypersensitivity

Rare cases of hypersensitivity reactions have been reported, including:

• Urticaria (hives)
• Rash
• Pruritus (generalized itching, distinct from injection site pruritus)
• Facial edema

Tesamorelin should be discontinued if a hypersensitivity reaction occurs.

Contraindications (Per FDA Label)

• Active malignancy: Tesamorelin increases GH and IGF-1, which could promote tumor growth. Contraindicated in patients with active malignancy. Consider individual risk in patients with history of treated malignancy.
• Disruption of the hypothalamic-pituitary axis: Due to hypophysectomy, hypopituitarism, or pituitary tumor/surgery. Tesamorelin requires functional somatotrophs to work.
• Pregnancy: Contraindicated. Tesamorelin is Pregnancy Category X — it may cause fetal harm. Pregnancy testing should be performed before initiation and periodically during treatment in women of childbearing potential.
• Known hypersensitivity: To tesamorelin or any component of the formulation (including mannitol).

Drug Interactions

• Cortisol: Tesamorelin may increase cortisol levels. Patients on glucocorticoid replacement (e.g., for adrenal insufficiency) may need dose adjustment.
• Insulin and oral hypoglycemics: GH-mediated insulin resistance may require dose adjustment of diabetes medications.
• 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1): GH inhibits this enzyme, potentially reducing cortisone-to-cortisol conversion and affecting patients on cortisol replacement therapy.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Regulatory Status

FDA Approval History

What FDA Approval Means

Tesamorelin's FDA approval means it has undergone the full regulatory review process, including:

• Phase 1, 2, and 3 clinical trials demonstrating safety and efficacy
• FDA review of manufacturing processes, quality controls, and labeling
• Post-marketing surveillance and adverse event reporting
• Established prescribing information including dosing, contraindications, warnings, and monitoring requirements

This places tesamorelin in a distinct category from most other therapeutic peptides (e.g., BPC-157, thymosin beta-4), which lack FDA approval for any indication.

Compounding Pharmacy Access

Tesamorelin is also available through compounding pharmacies (503A and 503B facilities) for off-label use. Key considerations:

• A valid prescription from a licensed provider is required
• Compounding pharmacies may produce tesamorelin at lower cost than the branded product
• Compounded preparations are not subject to the same FDA review as the branded product but are regulated under state pharmacy boards and FDA compounding regulations
• Unlike some peptides that have been classified as Category 2 by the FDA (e.g., BPC-157), tesamorelin's status as an FDA-approved drug with a known safety profile supports its continued availability through compounding

WADA Prohibited Status

WADA prohibits tesamorelin under two categories:

• S2.3 — Growth Hormone Releasing Factors: Including GHRH and its analogs (sermorelin, tesamorelin, CJC-1295, etc.)
• Prohibited at all times (in-competition and out-of-competition)
• No Therapeutic Use Exemption (TUE) is typically granted for GHRH analogs in competitive sport
• Athletes subject to WADA testing should not use tesamorelin (WADA Prohibited List)

DEA Scheduling

Tesamorelin is not a controlled substance under the DEA Controlled Substances Act. It does not have abuse potential comparable to scheduled drugs. It is a prescription medication — not over-the-counter — but does not carry the additional restrictions associated with scheduled substances.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Insurance Coverage

For the FDA-approved indication (HIV-associated lipodystrophy): Many insurance plans and state Medicaid programs cover Egrifta SV with prior authorization. Requirements typically include documented HIV diagnosis, evidence of excess trunk fat by imaging (CT or MRI), and confirmation of active antiretroviral therapy. Specialty pharmacy coordination is usually required.

For off-label use: Insurance does not cover tesamorelin for non-HIV indications (body composition, anti-aging, NAFLD, cognitive support). All costs for off-label use are out-of-pocket, regardless of whether the brand or compounded product is used.

Patient Assistance Programs

Theratechnologies offers patient support programs for Egrifta SV that may include:

• Co-pay assistance for commercially insured patients
• Free drug programs for uninsured or underinsured patients who meet eligibility criteria
• Assistance with prior authorization and appeals

Factors Affecting Cost

• Brand vs. compounding: Branded Egrifta SV carries the highest cost but offers the greatest quality assurance and regulatory oversight. Compounding pharmacies offer lower pricing with adequate but less stringent oversight.
• Dosing frequency: The FDA-approved protocol is daily; off-label reduced-frequency protocols (5 days on / 2 off) can reduce monthly cost by approximately 30%.
• Provider consultation fees: Anti-aging and regenerative medicine clinics may charge consultation fees ($150–$400) in addition to medication cost.
• Lab monitoring: IGF-1, glucose, and lipid monitoring add periodic costs (typically $100–$300 per lab draw).

Cost Comparison: Tesamorelin vs. Related Treatments

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Myth: Tesamorelin is the same as taking growth hormone.

Answer: Tesamorelin is not growth hormone. It is a GHRH analog — it stimulates the pituitary to release the body's own GH in a natural pulsatile pattern. Direct GH administration (e.g., Genotropin, Norditropin) provides exogenous GH at continuous, non-physiological levels and bypasses the hypothalamic-pituitary feedback system. Tesamorelin preserves the somatostatin-mediated negative feedback loop, providing a natural ceiling on GH production. This distinction affects the side effect profile, with tesamorelin generally producing lower and more physiological GH/IGF-1 elevations than exogenous GH replacement (Stanley et al., 2014).

Myth: Tesamorelin is a weight loss drug.

Answer: The FDA label explicitly states that tesamorelin is not indicated for weight loss management. Phase 3 trials showed significant reduction in visceral adipose tissue (trunk fat) but no significant change in total body weight. Tesamorelin redistributes body composition — reducing visceral fat while potentially maintaining or increasing lean mass — but does not produce the total weight reduction associated with anti-obesity medications like semaglutide or tirzepatide (Falutz et al., 2007).

Myth: Once you reduce visceral fat with tesamorelin, the results are permanent.

Answer: Visceral fat returns upon discontinuation. The Phase 3 extension study demonstrated that patients rerandomized from tesamorelin to placebo experienced return of visceral fat toward baseline levels. Tesamorelin manages — but does not permanently resolve — excess visceral adiposity. Continued treatment is required to maintain benefits (Falutz et al., 2010).

Myth: Tesamorelin causes diabetes.

Answer: Growth hormone is a counter-regulatory hormone that can impair insulin sensitivity, raising a theoretical concern about diabetes risk. However, Phase 3 trial data showed no statistically significant increase in new-onset diabetes with tesamorelin vs. placebo. Small, generally non-significant increases in fasting glucose were observed. The FDA label recommends monitoring glucose and HbA1c during treatment, particularly in patients with pre-existing diabetes or pre-diabetes — but characterizing tesamorelin as "causing diabetes" overstates the evidence (FDA Label).

Myth: Tesamorelin causes cancer.

Answer: Tesamorelin is contraindicated in patients with active malignancy because GH and IGF-1 can theoretically promote tumor growth. This is a precautionary contraindication based on the biological plausibility of GH/IGF-1 effects on cell proliferation — not based on observed cancer incidence in clinical trials. Phase 3 trials did not show an increased rate of malignancy with tesamorelin. However, epidemiological studies have associated sustained IGF-1 elevation with modestly increased cancer risk in observational data, which is why IGF-1 monitoring is recommended (Stanley et al., 2014).

Myth: Tesamorelin only works for HIV patients.

Answer: The FDA indication is specific to HIV-associated lipodystrophy because that is the population in which Phase 3 trials were conducted. The mechanism of action — GHRH receptor agonism leading to pulsatile GH release and visceral fat lipolysis — is not HIV-specific. Clinical research in non-HIV contexts (NAFLD, cognitive function) has demonstrated effects consistent with the pharmacological mechanism. Off-label use for body composition in non-HIV patients is based on this mechanistic rationale, though large controlled trials in non-HIV populations have not been published.

Myth: Compounded tesamorelin is the same quality as Egrifta SV.

Answer: Compounding pharmacies produce tesamorelin under different regulatory standards than the branded product. Egrifta SV is manufactured under full FDA cGMP (current Good Manufacturing Practice) standards with extensive quality controls, batch testing, and post-marketing surveillance. Compounded preparations are regulated by state pharmacy boards and, for 503B facilities, by the FDA — but they do not undergo the same NDA review process. Quality is generally adequate from reputable compounding pharmacies, but it is not identical to the branded product's quality assurance framework.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• Tesamorelin is an FDA-approved GHRH analog — one of the few therapeutic peptides with full regulatory approval. It is approved as Egrifta SV for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
• It works by stimulating pulsatile endogenous GH release, not by providing exogenous GH. This preserves the natural feedback mechanisms and produces a more physiological hormonal response compared to direct GH administration.
• Phase 3 clinical trials demonstrated 15–18% reduction in visceral adipose tissue over 26 weeks, measured by CT scan. These are randomized, double-blind, placebo-controlled trials — the gold standard of clinical evidence.
• Additional published clinical research supports effects on liver fat reduction (NAFLD), prevention of hepatic fibrosis progression, and cognitive improvement in older adults.
• Effects reverse upon discontinuation. Visceral fat returns toward baseline when treatment is stopped. Continued use is required to maintain benefits.
• Common side effects include injection site reactions, arthralgia, peripheral edema, and myalgia. IGF-1 levels require monitoring. Tesamorelin is contraindicated with active malignancy and pregnancy.
• Cost ranges from $200–$1,000+ per month depending on brand vs. compounding pharmacy source. Insurance covers the brand product for HIV lipodystrophy; off-label use is out-of-pocket.
• Off-label use for body composition, anti-aging, NAFLD, and cognitive support is growing through compounding pharmacies, based on published clinical data and mechanistic rationale.

Who Might Consider Tesamorelin

Based on the available evidence and clinical practice patterns, tesamorelin may be worth discussing with a healthcare provider for individuals who:

• Have HIV-associated lipodystrophy with excess visceral fat (FDA-approved indication)
• Have significant visceral adiposity contributing to metabolic risk and have not achieved adequate improvement with lifestyle modification
• Have NAFLD or hepatic steatosis and are seeking pharmacological options
• Are experiencing age-related GH decline with associated body composition changes
• Have access to a knowledgeable provider who can prescribe, monitor IGF-1 levels, and manage treatment appropriately

Questions to Ask a Provider

• Am I a candidate for tesamorelin based on my medical history, including any history of malignancy?
• Should I use the branded product (Egrifta SV) or a compounded preparation, and why?
• How often will my IGF-1, glucose, and lipid levels be monitored?
• What are realistic expectations for visceral fat reduction in my case?
• How long should I plan to continue treatment, given that effects reverse upon discontinuation?
• Are there interactions with my current medications?
• Would imaging (CT or DEXA) at baseline and follow-up be appropriate to objectively measure response?

Sources & Further Reading

Pivotal Clinical Trials

• Falutz J, et al. (2007) — "Metabolic effects of a growth hormone–releasing factor in patients with HIV" — New England Journal of Medicine
• Falutz J, et al. (2010) — "Effects of tesamorelin (TH9507), a growth hormone–releasing factor analog, in HIV-infected patients with abdominal fat accumulation" — Journal of Clinical Endocrinology & Metabolism

Liver Fat and NAFLD

• Stanley TL, et al. (2014) — "Effects of tesamorelin on hepatic fat and metabolic parameters in HIV-associated NAFLD" — Journal of Clinical Endocrinology & Metabolism
• Stanley TL, et al. (2019) — "Effect of tesamorelin on hepatic steatosis and fibrosis in HIV" — JAMA Network Open

Cognitive Function

• Baker LD, et al. (2012) — "Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults" — Archives of Neurology

Mechanism of Action & Physiology

• Stanley TL, Grinspoon SK (2014) — "Effects of growth hormone–releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies" — Growth Hormone & IGF Research

Regulatory & Prescribing Information

• Egrifta SV — Full Prescribing Information (FDA Label)
• FDA Drugs@FDA — Egrifta (tesamorelin) Approval History
• WADA — Prohibited List (Growth Hormone Releasing Factors — S2.3)

Manufacturer

• Theratechnologies Inc. — Manufacturer of Egrifta SV

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.